IMPACT Therapeutics

Impact Therapeutics is a China-based biopharmaceutical company that develops and commercializes PARP inhibitor therapies for the treatment of cancer.

Business Model:

Revenue: $7M

Employees: 11-50

Detailed IMPACT Therapeutics Information

Geographic Data

IMPACT Therapeutics headquarters map

Address: 399 Haiyang West Road, Pudong New Area

City: Shanghai

State: jiangsu province

Zip: 210061

Country: CN

Financial Info

Stage:

series d

Raised Last:

$0

Raised Total:

$40M

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Impact Therapeutics is a China-based biopharmaceutical company that develops and commercializes PARP inhibitor therapies for the treatment of cancer.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
7/2014 Series A 3 - Cenova
Lilly Asia Ventures
WuXi Healthcare Ventures
Cenova
Lilly Asia Ventures
WuXi Healthcare Ventures
3/2022 Series D -
2/2016 Series B 6 $10M BioVenture
China Summit Capital
Guangzhou Yuexiu Industrial Investment Fund
Haibang Capital
Lilly Asia Ventures
Summit Capital
BioVenture
China Summit Capital
Guangzhou Yuexiu Industrial Investment Fund
Haibang Capital
Lilly Asia Ventures
Summit Capital
3/2022 Series D 9 - Bestride
C&a;D Emerging Investment
CCBT Private Equity
China Summit Capital
Dingxin Capital
Exome Asset Management
Lilly Asia Ventures
Sam Isaly
Yuexiu Group
Bestride
C&a;D Emerging Investment
CCBT Private Equity
China Summit Capital
Dingxin Capital
Exome Asset Management
Lilly Asia Ventures
Sam Isaly
Yuexiu Group
8/2018 Series C 2 $30M Decheng Capital
Lilly Asia Ventures
Decheng Capital
Lilly Asia Ventures
12/2020 Series C $0 AJ Asset Management
China Summit Capital
Lilly Asia Ventures
Shanghai Junshi Biosciences
West Fountain Global Fund
Zhejiang Ausun Pharmaceutical
Zhenji Capital
AJ Asset Management
China Summit Capital
Lilly Asia Ventures
Shanghai Junshi Biosciences
West Fountain Global Fund
Zhejiang Ausun Pharmaceutical
Zhenji Capital
3/2022 Series D - Dingxin Capital
Exome Asset Management LLC
Lilly Asia Ventures
YUEXIU FINANCIAL HOLDINGS GROUP CO.LTD.
Dingxin Capital
Exome Asset Management LLC
Lilly Asia Ventures
YUEXIU FINANCIAL HOLDINGS GROUP CO.LTD.
3/2022 Series D 9 - Bestride
C&a;D Emerging Investment
CCBT Private Equity
China Summit Capital
Dingxin Capital
Exome Asset Management
Lilly Asia Ventures
Sam Isaly
Yuexiu Group
Bestride
C&a;D Emerging Investment
CCBT Private Equity
China Summit Capital
Dingxin Capital
Exome Asset Management
Lilly Asia Ventures
Sam Isaly
Yuexiu Group
12/2020 Series C 7 $50M AJ Asset Management
China Summit Capital
Lilly Asia Ventures
Shanghai Junshi Biosciences
West Fountain Global Fund
Zhejiang Ausun Pharmaceutical
Zhenji Capital
AJ Asset Management
China Summit Capital
Lilly Asia Ventures
Shanghai Junshi Biosciences
West Fountain Global Fund
Zhejiang Ausun Pharmaceutical
Zhenji Capital
7/2014 Series A 3 - Cenova
Lilly Asia Ventures
WuXi Healthcare Ventures
Cenova
Lilly Asia Ventures
WuXi Healthcare Ventures
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research